Skip to content
You can now search across every topic, entity and event.What's new
UK Startups and Innovation
13MAY

CellCentric raises Europe's largest 2026 biotech round

4 min read
20:05UTC

CellCentric closed a $220m Series D on 5 May led by Venrock Healthcare Capital Partners, with Pfizer and Fidelity co-investing: Europe's largest private biotech financing of 2026, drawn entirely from private capital.

← Back to State capital lands on UK tech in nine daysJump to analysis ↓
TechnologyDeveloping
Key takeaway

CellCentric's $220m Series D with Pfizer proves UK oncology commands US-sized rounds without public subsidy.

CellCentric closed a $220m Series D on 5 May 2026, which BioSpace and BioPharma Dive reported as the largest private biotech financing in Europe in 2026. 1 Venrock Healthcare Capital Partners led; Fidelity Management and Research, Sofinnova Partners, HBM Healthcare, RA Capital Management, Forbion, Pfizer, Avego BioScience Capital, and the American Cancer Society BrightEdge initiative co-invested.

The capital funds Phase 2 DOMMINO-1 trials, running in both the UK and the United States, for inobrodib, an oral p300/CBP (a histone acetyltransferase target) inhibitor for relapsed and refractory multiple myeloma. Phase 3 (DOMMINO-2) is planned for H2 2026. inobrodib's oral formulation is clinically significant: multiple myeloma treatment is predominantly infusion-based today, and an oral option changes the outpatient economics of treatment substantially for a patient population that requires long-term maintenance therapy.

Pfizer's entry at Phase 2 stage is the signal that compresses the typical trade-sale timeline. When a major pharmaceutical company enters a Series D alongside a Phase 2 readout, it is typically conducting buy-versus-build analysis in parallel: the equity position gives Pfizer visibility into the DOMMINO-1 data before it is public. For CellCentric, that creates a dual path to liquidity: a Phase 3 success that supports an independent listing, or an acquisition by a strategic already inside the syndicate.

No UK public investor participated in the round. CellCentric kept its Phase 2 and capital fully in the UK without any state anchor. At $220m with Pfizer in, public capital was neither needed nor sought. The FCA and PRA had cut SM&CR (Senior Managers and Certification Regime) certification roles by 15% on 22 April , reducing regulatory overhead for authorised financial participants in biotech rounds, a signal that the UK regulatory environment is loosening at both the investment and company level simultaneously. UK oncology founders with credible Phase 2 data can now argue for a US-sized Series D from London; the Boston relocation pressure has dropped a notch.

Deep Analysis

In plain English

CellCentric is developing a cancer drug called inobrodib for multiple myeloma, a blood cancer that affects the bone marrow. Inobrodib is taken as a tablet rather than an infusion, which matters enormously for patients who need long-term treatment: monthly infusion clinic visits over years are exhausting and disruptive to daily life. The company raised $220m in May 2026, described as the largest private funding round for a European biotech company in 2026. Pfizer, one of the world's largest pharmaceutical companies, invested alongside US and European specialist healthcare funds. The money funds Phase 2 clinical trials in the UK and US, with a larger Phase 3 global trial planned for the second half of 2026. No UK government money joined the round; the BBB's £40m-per-company cap would have covered less than 20% of the $220m raise, and Venrock, Pfizer, and Fidelity filled the syndicate without it.

Deep Analysis
Root Causes

Multiple myeloma's relapsed/refractory segment represents a structural market failure in oncology: patients exhaust approved therapies faster than new approvals arrive, creating a persistent unmet need that Pfizer, J&J, and BMS have all tried to address through acquisitions and licensing.

CellCentric's oral formulation addresses a specific constraint in the relapsed segment: patients receiving maintenance therapy over years find infusion-based treatments logistically unsustainable, and an oral agent that maintains efficacy while eliminating infusion clinic visits has health-economics advantages independent of clinical differentiation.

The DOMMINO-1 Phase 2 running simultaneously in the UK and US is a regulatory strategy as much as a clinical one: dual-jurisdiction Phase 2 data compresses the time to Biologics License Application in the US while supporting a UK Medicines and Healthcare products Regulatory Agency (MHRA) submission from the same dataset.

What could happen next?
  • Opportunity

    Pfizer's Series D equity position creates a structured acquisition option that CellCentric can exercise via a Phase 3 success: a bilateral deal with Pfizer already inside the syndicate avoids a competitive auction process and provides balance-sheet certainty for the development programme.

  • Consequence

    CellCentric's $220m with no BBB participation, on the same day as Cytospire's oversubscribed BBB-backed round, establishes that UK oncology companies with credible Phase 2 assets do not require public co-investment to close US-scale rounds; the BBB's additionality case is stronger in early-stage rounds where private lead investors are absent.

Sources:BioSpace
Mentions:inobrodib →CellCentric →Venrock Healthcare Capital Partners →Pfizer →Sofinnova Partners →Forbion →Phase 3 →Senior Managers and Certification Regime →United States →Boston →Paris →Nasdaq →Fidelity →American Cancer Society BrightEdge →BioSpace →BioPharma Dive →HBM Healthcare →RA Capital Management →Avego BioScience Capital →
First Reported In

Update #4 · State capital lands on UK tech in nine days

BioSpace· 13 May 2026
Read original →
Different Perspectives
Institute of Physics
Institute of Physics
The Institute has long argued STFC's national-laboratory infrastructure, not its grant programmes, is the binding constraint on UK physics output, and warns mothballing capacity like Clara removes capability that cannot be rebuilt on a four-year cycle. It represents the discovery-science community absorbing the reallocation the Bank's equity cheques do not touch.
Helsing
Helsing
The Munich-headquartered defence-AI firm chose Plymouth over Continental sites for a £350m manufacturing plant building underwater surveillance gliders, alongside its record raise. Its choice of postcode signals confidence in UK manufacturing capacity for defence hardware even as it looks abroad for the capital financing that hardware.
Dragoneer Investment Group, Lightspeed Venture Partners and Iconiq
Dragoneer Investment Group, Lightspeed Venture Partners and Iconiq
The three US growth-capital firms backed Helsing's $1.8bn round at an $18bn valuation, more than doubling the mark set only a year earlier, with demand reportedly exceeding the capital on offer. Their money, not a UK sovereign vehicle, is what funds the Plymouth plant, extending a pattern of foreign capital underwriting British defence-hardware manufacturing this cycle.
British Business Bank
British Business Bank
The Bank wrote its largest-ever direct life-sciences cheque into Alchemab and added a £6.5bn SME lending guarantee the same week UKRI confirmed the STFC cuts. It is deploying an April mandate change letting it lead venture rounds and invest directly up to £60m per company, treating equity extension rounds and small-business debt as newly within its risk appetite.
Daphni
Daphni
The Paris seed fund joined Speedinvest and three UK backers in Astral Systems' GBP23m Series A for modular fusion reactors, one of the round's five European co-investors betting on lab-to-market fusion ahead of any working commercial reactor. Unlike CuspAI's all-foreign cap table, this round kept a UK lead investor in Mercia Ventures.
EQT
EQT
EQT, appointed by the European Innovation Council to run the EUR5bn Scaleup Europe Fund, entered advanced talks for a further CuspAI stake reported on 3 July, the fund's first pursuit of a UK-founded winner. A closed deal would put EU sovereign capital, not a UK vehicle, on the cap table of a company Britain's own funds passed over.